Windtree Therapeutics Overview
- Year Founded
-
1992
- Status
-
Public
- Employees
-
20
- Stock Symbol
-
WINT
- Investments
-
5
- Share Price
-
$2.05
- (As of Friday Closing)
Windtree Therapeutics General Information
Description
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Contact Information
Website
www.windtreetx.comCorporate Office
- 2600 Kelly Road
- Suite 100
- Warrington, PA 18976-3622
- United States
Corporate Office
- 2600 Kelly Road
- Suite 100
- Warrington, PA 18976-3622
- United States
Windtree Therapeutics Stock Performance
As of 14-Mar-2025, Windtree Therapeutics’s stock price is $2.05. Its current market cap is $1.54M with 749K shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.05 | $2.06 | $1.78 - $737.43 | $1.54M | 749K | 336K | -$1.1K |
Windtree Therapeutics Financials Summary
As of 30-Sep-2024, Windtree Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 12,378 | (1,507) | 905 | 24,024 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (9,484) | (20,466) | (40,098) | (77,408) |
| Net Income | (9,708) | (20,291) | (39,208) | (67,636) |
| Total Assets | 30,448 | 32,406 | 37,954 | 74,789 |
| Total Debt | 2,013 | 1,830 | 2,280 | 2,893 |
Windtree Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Windtree Therapeutics Comparisons
Industry
Financing
Details
Windtree Therapeutics Competitors (21)
One of Windtree Therapeutics’s 21 competitors is Vasa Therapeutics, a Venture Capital-Backed company based in Encinitas, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vasa Therapeutics | Venture Capital-Backed | Encinitas, CA | ||||
| Aqualung Therapeutics | Venture Capital-Backed | Tucson, AZ | ||||
| Verve Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Avalyn Pharma | Venture Capital-Backed | Cambridge, MA | ||||
| hVIVO | Formerly VC-backed | London, United Kingdom |
Windtree Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Windtree Therapeutics Patents
Windtree Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023256547-A1 | Istaroxime-containing intravenous formulation for the treatment of pre-cardiogenic shock and cardiogenic shock | Pending | 20-Apr-2022 | ||
| EP-4511040-A1 | Istaroxime-containing intravenous formulation for the treatment of pre-cardiogenic shock and cardiogenic shock | Pending | 20-Apr-2022 | ||
| US-20240293426-A1 | Intravenous istaroxime for the treatment of acute heart failure | Pending | 22-Jan-2021 | ||
| CA-3149938-A1 | Androstane derivatives with activity as pure or predominantly pure stimulators of serca2a for the treatment of heart failure | Pending | 09-Oct-2019 | ||
| AU-2020363865-A1 | Androstane derivatives with activity as pure or predominantly pure stimulators of serca2a for the treatment of heart failure | Pending | 09-Oct-2019 | C07J1/0011 |
Windtree Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Windtree Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Windtree Therapeutics Investments & Acquisitions (5)
Windtree Therapeutics’s most recent deal was a Merger/Acquisition with Varian Biopharmaceuticals for . The deal was made on 02-Apr-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Varian Biopharmaceuticals | 02-Apr-2024 | Merger/Acquisition | Pharmaceuticals | ||
| KatKin | 08-Aug-2022 | Early Stage VC | Other Consumer Non-Durables | ||
| CVie Therapeutics Company | 21-Dec-2018 | Merger/Acquisition | Drug Discovery | ||
| AEROSURF | 15-Oct-2014 | Joint Venture | Managed Care | ||
| Laureate Pharma (Manufacturing Operations) | 03-Jan-2006 | Merger/Acquisition | Biotechnology |
Windtree Therapeutics FAQs
-
When was Windtree Therapeutics founded?
Windtree Therapeutics was founded in 1992.
-
Where is Windtree Therapeutics headquartered?
Windtree Therapeutics is headquartered in Warrington, PA.
-
What is the size of Windtree Therapeutics?
Windtree Therapeutics has 20 total employees.
-
What industry is Windtree Therapeutics in?
Windtree Therapeutics’s primary industry is Biotechnology.
-
Is Windtree Therapeutics a private or public company?
Windtree Therapeutics is a Public company.
-
What is Windtree Therapeutics’s stock symbol?
The ticker symbol for Windtree Therapeutics is WINT.
-
What is the current stock price of Windtree Therapeutics?
As of 14-Mar-2025 the stock price of Windtree Therapeutics is $2.05.
-
What is the current market cap of Windtree Therapeutics?
The current market capitalization of Windtree Therapeutics is $1.54M.
-
Who are Windtree Therapeutics’s competitors?
Vasa Therapeutics, Aqualung Therapeutics, Verve Therapeutics, Avalyn Pharma, and hVIVO are some of the 21 competitors of Windtree Therapeutics.
-
What is Windtree Therapeutics’s annual earnings per share (EPS)?
Windtree Therapeutics’s EPS for 12 months was -$1.1K.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
